Insider trade

Officer sold ~$1.22M of ABBV shares in the open market

Traded Mar 4, 2026 · Filed Mar 6, 2026

AbbVieABBV

~$1.22M
Reported value · 5,230 sh @ $233.56: 2,654
Holds after · shares reported: +10.1%
stock since the trade · S&P 500 +11.5%, $236.19 → $259.93 on Oct 1

Why it stands out

AbbVie's SVP, Controller sold $1.22M of AbbVie shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Mar 4, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 6, 2026

Officer$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,221,519

Shares × reported transaction price

Timing vs results

28 days after results of Feb 4, 2026, 30 days before results of Apr 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $236.19 on Mar 4, 2026, within 4% of its 52-week high, after a 10% rise over the previous 30 trading days

52-week range $170.16 (Apr 21, 2025) to $244.38 (Oct 1, 2025), 89% of the way up, from 251 adjusted closes. 30 trading days earlier: $214.04 on Jan 20, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Skyrizi on Mar 6, 2026, 2 days after this trade.

New use approved (efficacy supplement). Active ingredient: Risankizumab-Rzaa. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-2.6%	-1.4%	-1.3%
30 days	-7.0%	-0.3%	-6.6%
90 days	-1.9%	+9.0%	-10.9%
180 days	+9.4%	+12.9%	-3.5%

Past results only. Not a forecast.

Source receipt

Record ID: 0002057696-26-000008
Filed / recorded: Mar 6, 2026, 10:05 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: AbbVie Inc.
Issuer CIK: 1551152
Ticker: ABBV
Reporting person: David Ryan Purdue
Relationship: Officer
Officer title: SVP, Controller
Security: Common Stock, $0.01 par value
Table: Non-derivative (Table I)
Transaction date: Mar 4, 2026
Transaction code: S
Shares / units: 5,230
Price per share: $233.56
Acquired / disposed: Disposed (D)
Shares owned after: 2,654
Ownership form: Direct
Amendment: No

Around the same time

6mo ago

71Derivative units · @ $217.49

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

6mo ago

155Derivative units · @ $217.49

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

6mo ago

35Derivative units · @ $217.49

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

Why it stands out

Dates, kept separate

Context

After it was reported

Source receipt

Around the same time

71Derivative units · @ $217.49

155Derivative units · @ $217.49

35Derivative units · @ $217.49

Most active this month